

Marcela F Pasetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7609550/publications.pdf>

Version: 2024-02-01

121
papers

5,534
citations

71061

41
h-index

88593

70
g-index

128
all docs

128
docs citations

128
times ranked

5567
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. <i>Nature Reviews Microbiology</i> , 2007, 5, 540-553.	13.6	303
2	A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. <i>Scientific Reports</i> , 2017, 7, 45270.	1.6	274
3	Immunology of gut mucosal vaccines. <i>Immunological Reviews</i> , 2011, 239, 125-148.	2.8	207
4	Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody-Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues. <i>Journal of Infectious Diseases</i> , 2010, 202, 1649-1658.	1.9	200
5	Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. <i>Lancet Infectious Diseases</i> , 2016, 16, 1026-1035.	4.6	196
6	Safety and Immunogenicity of a Vi Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 393-402.	2.9	164
7	Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. <i>Vaccine</i> , 2004, 22, 4385-4389.	1.7	163
8	Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With <i>Vibrio cholerae</i> O1 El Tor. <i>Clinical Infectious Diseases</i> , 2016, 62, 1329-1335.	2.9	154
9	Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. <i>Gut</i> , 2015, 64, 77-83.	6.1	145
10	Characterization of CD8+ Effector T Cell Responses in Volunteers Immunized with <i>Salmonella enterica</i> Serovar Typhi Strain Ty21a Typhoid Vaccine. <i>Journal of Immunology</i> , 2002, 169, 2196-2203.	0.4	139
11	Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins. <i>Infection and Immunity</i> , 2012, 80, 1222-1231.	1.0	124
12	Progress and pitfalls in Shigella vaccine research. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 245-255.	8.2	117
13	<i>Salmonella enterica</i> Serovar Enteritidis Core O Polysaccharide Conjugated to H ₂ G _m Flagellin as a Candidate Vaccine for Protection against Invasive Infection with <i>S. enteritidis</i> . <i>Infection and Immunity</i> , 2011, 79, 4240-4249.	1.0	114
14	<i>Salmonella enterica</i> serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. <i>Cancer Medicine</i> , 2016, 5, 3310-3235.	1.3	102
15	Concomitant Induction of CD4+ and CD8+ T Cell Responses in Volunteers Immunized with <i>Salmonella enterica</i> Serovar Typhi Strain CVD 908-htrA. <i>Journal of Immunology</i> , 2003, 170, 2734-2741.	0.4	94
16	Animal models paving the way for clinical trials of attenuated <i>Salmonella enterica</i> serovar Typhi live oral vaccines and live vectors. <i>Vaccine</i> , 2003, 21, 401-418.	1.7	91
17	Cytokines Are Markers of the <i>Clostridium difficile</i> -Induced Inflammatory Response and Predict Disease Severity. <i>Vaccine Journal</i> , 2017, 24, .	3.2	90
18	Engineering and Preclinical Evaluation of Attenuated Nontyphoidal <i>Salmonella</i> Strains Serving as Live Oral Vaccines and as Reagent Strains. <i>Infection and Immunity</i> , 2011, 79, 4175-4185.	1.0	89

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. <i>JCI Insight</i> , 2018, 3, .	2.3	89
20	Deletion in the <i>Shigella</i> Enterotoxin Genes Further Attenuates <i>Shigella flexneri</i> 2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208. <i>Journal of Infectious Diseases</i> , 2004, 190, 1745-1754.	1.9	86
21	In Vivo Characterization of the Murine Intranasal Model for Assessing the Immunogenicity of Attenuated <i>Salmonella enterica</i> Serovar Typhi Strains as Live Mucosal Vaccines and as Live Vectors. <i>Infection and Immunity</i> , 2000, 68, 205-213.	1.0	79
22	<i>Salmonella enterica</i> serovar Typhi live vector vaccines finally come of age. <i>Immunology and Cell Biology</i> , 2009, 87, 400-412.	1.0	77
23	Attenuated <i>Salmonella enterica</i> Serovar Typhi and <i>Shigella flexneri</i> 2a Strains Mucosally Deliver DNA Vaccines Encoding Measles Virus Hemagglutinin, Inducing Specific Immune Responses and Protection in Cotton Rats. <i>Journal of Virology</i> , 2003, 77, 5209-5217.	1.5	72
24	Safety and Immunogenicity of CVD 1208S, a Live, Oral <i>guaBA</i> ⁻ <i>sen</i> ⁻ <i>set</i> <i>Shigella flexneri</i> 2a Vaccine Grown on Animal-Free Media. <i>Hum Vaccin</i> , 2007, 3, 268-275.	2.4	72
25	Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. <i>Vaccine Journal</i> , 2017, 24, .	3.2	69
26	Immune Responses to an Oral Typhoid Vaccine Strain That Is Modified to Constitutively Express Vi Capsular Polysaccharide. <i>Journal of Infectious Diseases</i> , 2004, 190, 565-570.	1.9	68
27	Attenuated <i>guaBA</i> <i>Salmonella typhi</i> Vaccine Strain CVD 915 as a Live Vector Utilizing Prokaryotic or Eukaryotic Expression Systems to Deliver Foreign Antigens and Elicit Immune Responses. <i>Clinical Immunology</i> , 1999, 92, 76-89.	1.4	67
28	Adaptation of the Endogenous <i>Salmonella enterica</i> Serovar Typhi <i>clyA</i> -Encoded Hemolysin for Antigen Export Enhances the Immunogenicity of Anthrax Protective Antigen Domain 4 Expressed by the Attenuated Live-Vector Vaccine Strain CVD 908- <i>htrA</i> . <i>Infection and Immunity</i> , 2004, 72, 7096-7106.	1.0	67
29	Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> . <i>PLoS ONE</i> , 2018, 13, e0203143.	1.1	67
30	Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1088-1096.	4.6	63
31	Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal <i>Salmonella</i> Vaccines. <i>Vaccine Journal</i> , 2014, 21, 712-721.	3.2	62
32	Oral priming with <i>Salmonella Typhi</i> vaccine strain CVD 909 followed by parenteral boost with the <i>S. Typhi</i> Vi capsular polysaccharide vaccine induces CD27 ⁺ IgD ⁺ <i>S. Typhi</i> -specific IgA and IgG B memory cells in humans. <i>Clinical Immunology</i> , 2011, 138, 187-200.	1.4	56
33	Safety and Immunogenicity of a Single Oral Dose of Recombinant Double Mutant Heat-Labile Toxin Derived from Enterotoxigenic <i>Escherichia coli</i> . <i>Vaccine Journal</i> , 2013, 20, 1764-1770.	3.2	54
34	Live Oral <i>Salmonella enterica</i> Serovar Typhi Vaccines Ty21a and CVD 909 Induce Opsonophagocytic Functional Antibodies in Humans That Cross-React with <i>S. Paratyphi A</i> and <i>S. Paratyphi B</i> . <i>Vaccine Journal</i> , 2014, 21, 427-434.	3.2	52
35	Intradermal Delivery of <i>Shigella</i> IpaB and IpaD Type III Secretion Proteins: Kinetics of Cell Recruitment and Antigen Uptake, Mucosal and Systemic Immunity, and Protection across Serotypes. <i>Journal of Immunology</i> , 2014, 192, 1630-1640.	0.4	52
36	Construction, Genotypic and Phenotypic Characterization, and Immunogenicity of Attenuated <i>guaBA</i> <i>Salmonella enterica</i> Serovar Typhi Strain CVD 915. <i>Infection and Immunity</i> , 2001, 69, 4734-4741.	1.0	49

#	ARTICLE	IF	CITATIONS
37	Sustained Protection in Mice Immunized with Fractional Doses of Salmonella Enteritidis Core and O Polysaccharide-Flagellin Glycoconjugates. PLoS ONE, 2013, 8, e64680.	1.1	49
38	An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine, 2008, 26, 1773-1785.	1.7	48
39	Cell-Associated Flagella Enhance the Protection Conferred by Mucosally-Administered Attenuated Salmonella Paratyphi A Vaccines. PLoS Neglected Tropical Diseases, 2011, 5, e1373.	1.3	48
40	Neonatal Immunization with a Sindbis Virus-DNA Measles Vaccine Induces Adult-Like Neutralizing Antibodies and Cell-Mediated Immunity in the Presence of Maternal Antibodies. Journal of Immunology, 2006, 176, 5671-5681.	0.4	44
41	Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine, 2013, 31, 2919-2929.	1.7	44
42	Safety and Immunogenicity of Single-Dose Live Oral Cholera Vaccine Strain CVD 103-HgR, Prepared from New Master and Working Cell Banks. Vaccine Journal, 2014, 21, 66-73.	3.2	43
43	<i>Shigella</i> IpaB and IpaD displayed on <i>L. lactis</i> bacterium-like particles induce protective immunity in adult and infant mice. Immunology and Cell Biology, 2015, 93, 641-652.	1.0	43
44	Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life. Clinical Infectious Diseases, 2021, 73, e4421-e4427.	2.9	42
45	A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine, 2000, 18, 3208-3213.	1.7	39
46	Mucosal Immunization with Attenuated <i>Salmonella enterica</i> Serovar Typhi Expressing Protective Antigen of Anthrax Toxin (PA83) Primes Monkeys for Accelerated Serum Antibody Responses to Parenteral PA83 Vaccine. Journal of Infectious Diseases, 2009, 199, 326-335.	1.9	38
47	A New Generation of Stable, Nonantibiotic, Low-Copy-Number Plasmids Improves Immune Responses to Foreign Antigens in <i>Salmonella enterica</i> Serovar Typhi Live Vectors. Infection and Immunity, 2010, 78, 337-347.	1.0	38
48	Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. Vaccine Journal, 2016, 23, 918-925.	3.2	38
49	A SEROSURVEY TO IDENTIFY THE WINDOW OF VULNERABILITY TO WILD-TYPE MEASLES AMONG INFANTS IN RURAL MALI. American Journal of Tropical Medicine and Hygiene, 2005, 73, 26-31.	0.6	38
50	Live Attenuated Human <i>Salmonella</i> Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity. EcoSal Plus, 2016, 7, .	2.1	35
51	A scalable method for biochemical purification of Salmonella flagellin. Protein Expression and Purification, 2014, 102, 1-7.	0.6	31
52	Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput <i>Shigella</i> Serum Bactericidal Assay. MSphere, 2018, 3, .	1.3	31
53	Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain "A" A phase 2 randomized clinical Trial. Vaccine, 2017, 35, 4730-4737.	1.7	30
54	Characterization of Immune Responses Induced by Intramuscular Vaccination with DNA Vaccines Encoding Measles Virus Hemagglutinin and/or Fusion Proteins. Journal of Virology, 2005, 79, 9854-9861.	1.5	29

#	ARTICLE	IF	CITATIONS
55	Measurement of Tetanus Antitoxin in Oral Fluid. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 819-825.	1.1	27
56	A Novel <i>Shigella</i> Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge. <i>MSphere</i> , 2018, 3, .	1.3	27
57	Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection. <i>Nature Communications</i> , 2021, 12, 3696.	5.8	27
58	Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine. <i>Vaccine Journal</i> , 2011, 18, 355-361.	3.2	26
59	<i>Salmonella enterica</i> Serovar Typhi Live Vector Vaccines Delivered Intranasally Elicit Regional and Systemic Specific CD8+ Major Histocompatibility Class I-Restricted Cytotoxic T Lymphocytes. <i>Infection and Immunity</i> , 2002, 70, 4009-4018.	1.0	24
60	Mucosally Delivered <i>Salmonella</i> Typhi Expressing the <i>Yersinia pestis</i> F1 Antigen Elicits Mucosal and Systemic Immunity Early in Life and Primes the Neonatal Immune System for a Vigorous Anamnestic Response to Parenteral F1 Boost. <i>Journal of Immunology</i> , 2009, 182, 1211-1222.	0.4	24
61	A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic <i>Escherichia coli</i> (ETEC) by sublingual or oral immunization. <i>Vaccine</i> , 2019, 37, 602-611.	1.7	24
62	Sindbis Virus-Based Measles DNA Vaccines Protect Cotton Rats against Respiratory Measles: Relevance of Antibodies, Mucosal and Systemic Antibody-Secreting Cells, Memory B Cells, and Th1-Type Cytokines as Correlates of Immunity. <i>Journal of Virology</i> , 2009, 83, 2789-2794.	1.5	22
63	Human immune responses against <i>Shigella</i> and enterotoxigenic <i>E. coli</i> : Current advances and the path forward. <i>Vaccine</i> , 2017, 35, 6803-6806.	1.7	22
64	Consensus Report on <i>Shigella</i> Controlled Human Infection Model: Immunological Assays. <i>Clinical Infectious Diseases</i> , 2019, 69, S596-S601.	2.9	22
65	Gut-Homing Conventional Plasmablasts and CD27 ^{hi} Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated <i>Shigella</i> Vaccine Candidate in Humans. <i>Frontiers in Immunology</i> , 2014, 5, 374.	2.2	21
66	A Bivalent Typhoid Live Vector Vaccine Expressing both Chromosome- and Plasmid-Encoded <i>Yersinia pestis</i> Antigens Fully Protects against Murine Lethal Pulmonary Plague Infection. <i>Infection and Immunity</i> , 2015, 83, 161-172.	1.0	21
67	Immunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia. <i>PLoS ONE</i> , 2016, 11, e0149970.	1.1	21
68	Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic <i>Escherichia coli</i> Hyperimmune Bovine Colostrum Products. <i>Vaccine Journal</i> , 2017, 24, .	3.2	21
69	Functional antibodies as immunological endpoints to evaluate protective immunity against <i>Shigella</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 197-205.	1.4	21
70	A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. <i>MBio</i> , 2021, 12, e0224121.	1.8	21
71	Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. <i>Biologicals</i> , 2018, 56, 29-38.	0.5	20
72	Safety and tolerability of a live oral <i>Salmonella typhimurium</i> vaccine candidate in SIV-infected nonhuman primates. <i>Vaccine</i> , 2013, 31, 5879-5888.	1.7	19

#	ARTICLE	IF	CITATIONS
73	Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella. PLoS ONE, 2016, 11, e0151875.	1.1	19
74	Helicobacter pylori Infection Affects Immune Responses Following Vaccination of Typhoid-Naive US Adults With Attenuated Salmonella Typhi Oral Vaccine CVD 908-htrA. Journal of Infectious Diseases, 2014, 209, 1452-1458.	1.9	18
75	Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. Vaccine, 2021, 39, 1195-1200.	1.7	18
76	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney International Reports, 2022, 7, 993-1003.	0.4	18
77	Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. Journal of Immunology, 2020, 205, 877-882.	0.4	17
78	Enterotoxigenic Escherichia coli is phagocytosed by macrophages underlying villus-like intestinal epithelial cells: modeling ex vivo innate immune defenses of the human gut. Gut Microbes, 2017, , 00-00.	4.3	16
79	Human Breast Milk Enhances Intestinal Mucosal Barrier Function and Innate Immunity in a Healthy Pediatric Human Enteroid Model. Frontiers in Cell and Developmental Biology, 2021, 9, 685171.	1.8	16
80	Characterization of a multicomponent live, attenuated Shigella flexneri vaccine. Pathogens and Disease, 2016, 74, ftw034.	0.8	15
81	Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice. PLoS Neglected Tropical Diseases, 2018, 12, e0006522.	1.3	15
82	Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis. Frontiers in Immunology, 2021, 12, 725129.	2.2	15
83	A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali. American Journal of Tropical Medicine and Hygiene, 2005, 73, 26-31.	0.6	15
84	Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. International Journal of Infectious Diseases, 2021, 108, 465-472.	1.5	14
85	Age-Dependent Association among Helicobacter pylori Infection, Serum Pepsinogen Levels and Immune Response of Children to Live Oral Cholera Vaccine CVD 103-HgR. PLoS ONE, 2014, 9, e83999.	1.1	14
86	Strategies for Coordination of a Serosurvey in Parallel with an Immunization Coverage Survey. American Journal of Tropical Medicine and Hygiene, 2015, 93, 416-424.	0.6	11
87	Opsonophagocytic Assay To Evaluate Immunogenicity of Nontyphoidal Salmonella Vaccines. Vaccine Journal, 2016, 23, 520-523.	3.2	11
88	Preclinical Safety and Biodistribution of Sindbis Virus Measles DNA Vaccines Administered as a Single Dose or Followed by Live Attenuated Measles Vaccine in a Heterologous Prime-Boost Regimen. Human Gene Therapy, 2008, 19, 522-531.	1.4	10
89	Refined Live Attenuated Salmonella enterica Serovar Typhimurium and Enteritidis Vaccines Mediate Homologous and Heterologous Serogroup Protection in Mice. Infection and Immunity, 2015, 83, 4504-4512.	1.0	10
90	Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis. PLoS Neglected Tropical Diseases, 2019, 13, e0007644.	1.3	10

#	ARTICLE	IF	CITATIONS
91	Altered Gut Microbiome and Fecal Immune Phenotype in Early Preterm Infants With Leaky Gut. <i>Frontiers in Immunology</i> , 2022, 13, 815046.	2.2	10
92	Highly Specialized Carbohydrate Metabolism Capability in <i>Bifidobacterium</i> Strains Associated with Intestinal Barrier Maturation in Early Preterm Infants. <i>MBio</i> , 2022, 13, .	1.8	10
93	Improved Tolerability of a <i>Salmonella enterica</i> Serovar Typhimurium Live-Attenuated Vaccine Strain Achieved by Balancing Inflammatory Potential with Immunogenicity. <i>Infection and Immunity</i> , 2018, 86, .	1.0	9
94	Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator. <i>Vaccine Journal</i> , 2017, 24, .	3.2	8
95	The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. <i>Immunity and Ageing</i> , 2020, 17, 9.	1.8	8
96	Epithelial and Neutrophil Interactions and Coordinated Response to <i>Shigella</i> in a Human Intestinal Enteroid-Neutrophil Coculture Model. <i>MBio</i> , 2022, 13, .	1.8	8
97	Improving Our Understanding of <i>Salmonella enterica</i> Serovar Paratyphi B through the Engineering and Testing of a Live Attenuated Vaccine Strain. <i>MSphere</i> , 2018, 3, .	1.3	7
98	Pregnancy level of estradiol attenuated virus-specific humoral immune response in H5N1-infected female mice despite inducing anti-inflammatory protection. <i>Emerging Microbes and Infections</i> , 2019, 8, 1146-1156.	3.0	7
99	Oral <i>Shigella</i> Vaccines. , 2020, , 515-536.		7
100	Functional and structural modifications of influenza antibodies during pregnancy. <i>IScience</i> , 2022, 25, 104088.	1.9	7
101	Evaluation of a standardised Vi poly-L-lysine ELISA for serology of Vi capsular polysaccharide antibodies. <i>Biologicals</i> , 2020, 66, 21-29.	0.5	6
102	Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2013, 36, 113-128.	0.7	5
103	Serological Monitoring Is Key To Sustain Progress of the Maternal and Neonatal Tetanus Elimination Initiative. <i>Vaccine Journal</i> , 2016, 23, 532-534.	3.2	5
104	Immunogenicity and Efficacy of Live-Attenuated <i>Salmonella</i> Typhimurium Vaccine Candidate CVD 1926 in a Rhesus Macaque Model of Gastroenteritis. <i>Infection and Immunity</i> , 2021, 89, e0008721.	1.0	5
105	Efficient production of immunologically active <i>Shigella</i> invasion plasmid antigens IpaB and IpaH using a cell-free expression system. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 401-414.	1.7	5
106	Simple method for purification of enterotoxigenic <i>Escherichia coli</i> fimbriae. <i>Protein Expression and Purification</i> , 2016, 119, 130-135.	0.6	4
107	A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against <i>Yersinia</i> Infection in Adult and Infant Mice. <i>Journal of Immunology</i> , 2019, 202, 2005-2016.	0.4	4
108	Pre-existing <i>Helicobacter pylori</i> serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults. <i>Scientific Reports</i> , 2020, 10, 16871.	1.6	4

#	ARTICLE	IF	CITATIONS
109	Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach. <i>Vaccine</i> , 2021, 39, 5802-5813.	1.7	4
110	Gut Immunology and Oral Vaccination. , 2013, , 59-84.		3
111	Maternal Antibodies Elicited by Immunization With an O- Polysaccharide Glycoconjugate Vaccine Protect Infant Mice Against Lethal Salmonella Typhimurium Infection. <i>Frontiers in Immunology</i> , 2019, 10, 2124.	2.2	2
112	Adjustments for oral fluid quality and collection methods improve prediction of circulating tetanus antitoxin: Approaches for correcting antibody concentrations detected in a non-invasive specimen. <i>Vaccine</i> , 2021, 39, 423-430.	1.7	2
113	Measles DNA vaccine priming for young infants. <i>Procedia in Vaccinology</i> , 2010, 2, 151-158.	0.4	1
114	Springtime for CVI. <i>Vaccine Journal</i> , 2016, 23, 247-247.	3.2	1
115	A Primary Human Macrophage-Enteroid Co-Culture Model to Investigate Mucosal Gut Physiology and Host-Pathogen Interactions. <i>Gastroenterology</i> , 2017, 152, S56-S57.	0.6	1
116	Measles susceptibility in maternal-infant dyads in Bamako, Mali. <i>Vaccine</i> , 2022, 40, 1316-1322.	1.7	1
117	The Legacy of CVI. <i>Vaccine Journal</i> , 2017, 24, .	3.2	0
118	Completion of an Experiment. <i>MSphere</i> , 2018, 3, .	1.3	0
119	mSphere of Influence: the View from the Microbiologists of the Future. <i>MSphere</i> , 2019, 4, .	1.3	0
120	Maternal and neonatal immunization in the Americas: The benefits, the hurdles, and the way forward. <i>Vaccine</i> , 2021, 39, B1-B2.	1.7	0
121	Live Attenuated Vectors: Have they Delivered?. , 0, , 72-86.		0